8-K ·Filed May 7, 2026
8-K Item 2.02: Earnings release
Actionable Insight • Neutral
Monitor ASCO 2026 data presentation on June 1 for SIM0505 as the primary near-term catalyst; cash runway supports operations through H1 2027 with no immediate financing risk.
Final — all horizons settled through T+60d
NXTC ▼ -40.78% at T+60d
NEUTRAL call -40.78% · α vs SPY -45.62% · entry $9.76 → $5.78
T+1d
+0.20%
call +0.20% · α -0.03%
$9.78
settled 6mo ago
T+5d
+5.02%
call +5.02% · α +3.56%
$10.25
settled 6mo ago
T+20d
-69.77%
call -69.77% · α -69.80%
$2.95
settled 5mo ago
T+60d
-40.78%
call -40.78% · α -45.62%
$5.78
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
NextCure reported Q1 2026 net loss of $9.8M ($1.87 per share), in line with consensus of $1.85. Cash burn continues with $29.7M at quarter-end, sufficient into H1 2027. Key catalyst is SIM0505 Phase 1 data at ASCO 2026 on June 1.
Key Financial Metrics
EPS
−$1.87
est −$1.85 · -1.1%
Revenue
$0.00
est $0.00 · 0.0%
Rating
in line
Key Facts
- Net loss per share $(1.87) vs consensus $(1.85) (in line)
- Cash, cash equivalents and marketable securities $29.7M, down from $41.8M in Dec 2025
- FDA Fast Track designation granted for SIM0505 in platinum-resistant ovarian cancer
- SIM0505 Phase 1 dose escalation data to be presented at ASCO 2026 on June 1
- Cash runway expected into first half of 2027 through proof-of-concept for SIM0505
Financial Impact
Net loss $9.8M, EPS $(1.87) vs $(1.85) consensus, cash burn $12.1M in Q1
net losscashEPS
Risk Factors
- Cash burn rate may require additional financing before proof-of-concept
- Clinical trial failure for SIM0505 or LNCB74
- Dilution from ATM equity program ($1.2M raised in Q1)
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-057171 |
| Document: nxtc-20260507x8k.htm | 0001104659-26-057171 |
| Document: 0001104659-26-057171-index-headers.html | 0001104659-26-057171 |
| Document: 0001104659-26-057171-index.html | 0001104659-26-057171 |
| Document: 0001104659-26-057171.txt | 0001104659-26-057171 |
| 8-K Data (Synthetic) | 0001104659-26-057171 |
17 reports for NXTC
75% Hit rate @ T+60 Went positive at some point 6 of 6 best @ T+60▲ +74.85%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 20, 2026 6d ago | SC 13G | $5.44 | awaiting T+60 | — | $5.22 (−3.95%) |
Sep 25, 2026 4w ago | 425 | $5.08 | awaiting T+60 | — | $5.22 (+2.85%) |
Sep 25, 2026 4w ago | 8-K | $5.08 | awaiting T+60 | — | $5.22 (+2.85%) |
Aug 10, 2026 11w ago | 425 | $6.73 | awaiting T+60 | — | $5.22 (+22.36%) |
Aug 4, 2026 11w ago | 425 | $5.78 | awaiting T+60 | — | $5.22 (−9.60%) |
Aug 3, 2026 12w ago | Insider Buy | $5.78 | awaiting T+60 | — | $5.22 (−9.60%) |
Jul 29, 2026 12w ago | Insider Buy | $5.03 $4.98 | ▼ −0.99% | ▼ −3.46% | $5.22 (+3.88%) |
Jul 14, 2026 14w ago | 425 / 8-K | $6.58 $6.56 | ▼ −0.30% | ▼ −3.68% | $5.22 (−20.59%) |
Jul 14, 2026 14w ago | 8-K | $6.58 $6.56 | ▲ +0.30% | ▲ +3.68% | $5.22 (+20.59%) |
Jun 1, 2026 21w ago | 8-K | $3.38 $5.91 | ▲ +74.85% | ▲ +73.62% | $5.22 (+54.59%) |
Showing 10 of 17
US Market Status
Market Closed — Opens in 3h 53m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers